Cargando…

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049858/
https://www.ncbi.nlm.nih.gov/pubmed/33880006
http://dx.doi.org/10.1007/s40274-021-7640-0
_version_ 1783679499078991872
collection PubMed
description
format Online
Article
Text
id pubmed-8049858
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80498582021-04-16 Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia PharmacoEcon Outcomes News Clinical Study Springer International Publishing 2021-04-17 2021 /pmc/articles/PMC8049858/ /pubmed/33880006 http://dx.doi.org/10.1007/s40274-021-7640-0 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Study
Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
title Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
title_full Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
title_fullStr Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
title_full_unstemmed Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
title_short Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
title_sort primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049858/
https://www.ncbi.nlm.nih.gov/pubmed/33880006
http://dx.doi.org/10.1007/s40274-021-7640-0